- Home
- BMRC vs AVIR Comparison
BMRC vs AVIR Comparison
Compare BMRC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- AVIR
- Stock Information
- Founded
- BMRC 1989
- AVIR 2012
- Country
- BMRC United States
- AVIR United States
- Employees
- BMRC N/A
- AVIR N/A
- Industry
- BMRC Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- BMRC Finance
- AVIR Health Care
- Exchange
- BMRC Nasdaq
- AVIR Nasdaq
- Market Cap
- BMRC 334.0M
- AVIR 284.6M
- IPO Year
- BMRC N/A
- AVIR 2020
- Fundamental
- Price
- BMRC $23.70
- AVIR $3.24
- Analyst Decision
- BMRC Strong Buy
- AVIR Hold
- Analyst Count
- BMRC 3
- AVIR 1
- Target Price
- BMRC $28.00
- AVIR $6.88
- AVG Volume (30 Days)
- BMRC 54.3K
- AVIR 505.9K
- Earning Date
- BMRC 01-27-2025
- AVIR 02-26-2025
- Dividend Yield
- BMRC 4.21%
- AVIR N/A
- EPS Growth
- BMRC N/A
- AVIR N/A
- EPS
- BMRC N/A
- AVIR N/A
- Revenue
- BMRC $59,368,000.00
- AVIR N/A
- Revenue This Year
- BMRC N/A
- AVIR N/A
- Revenue Next Year
- BMRC $13.55
- AVIR N/A
- P/E Ratio
- BMRC N/A
- AVIR N/A
- Revenue Growth
- BMRC N/A
- AVIR N/A
- 52 Week Low
- BMRC $14.11
- AVIR $2.75
- 52 Week High
- BMRC $27.11
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- BMRC 50.49
- AVIR 47.81
- Support Level
- BMRC $23.10
- AVIR $3.11
- Resistance Level
- BMRC $24.00
- AVIR $3.49
- Average True Range (ATR)
- BMRC 0.79
- AVIR 0.14
- MACD
- BMRC 0.07
- AVIR -0.00
- Stochastic Oscillator
- BMRC 66.79
- AVIR 26.58
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).